Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus CORTEF ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus CORTEF ACETATE.
ARAZLO vs CORTEF ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Corticosteroid with anti-inflammatory and immunosuppressant activity; binds to glucocorticoid receptors, modulating gene expression and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Adult: 5-60 mg orally every 6-12 hours (hydrocortisone base equivalent), or 10-240 mg IV/IM every 12 hours (as hydrocortisone sodium succinate). Dose depends on severity and condition.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Plasma terminal half-life is approximately 1.5-2 hours. However, biologic half-life (duration of adrenal suppression) is 18-36 hours due to intracellular receptor binding.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily renal as inactive metabolites; less than 5% unchanged. Biliary/fecal elimination is minimal (<2%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid